; or (2) section 912a of title 10, United States Code (article 112a of the Uniform Code of Military Justice). (e) Additional authority In addition to awarding grants under this section, the Secretary shall provide funds for a clinical research trial using covered psychedelic substances that is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) and includes members of the Armed Forces as participants in the trial. (f) Report required Not later than 180 days after the date of the enactment of this Act, and every 180 days thereafter, the Secretary shall submit to the Committees on Armed Services of the House of Representatives and the Senate a report on grants awarded under this section, including the following: (1) Identification of clinics designated to host activities under such a grant. (2) A description of entities to whom the Secretary has awarded such a grant. (3) The number of members of the Armed Forces who participated in a clinical trial described in subsection (d). (4) Information on the findings of such clinical trials. (g) Authorization of appropriations There is authorized to be appropriated to the Secretary to carry out this section $15,000,000 for each of fiscal years 2024 through 2028. (h) Definitions In this section: (1) The term covered condition means any of the following: (A) Post-traumatic stress. (B) Traumatic brain injury. (C) Chronic traumatic encephalopathy (2) The term covered psychedelic substances means any of the following: (A) 3,4-Methylenedioxy-methamphetamine (commonly known as MDMA ). (B) Psilocybin. (C) Ibogaine. (D) 5-Methoxy-N,N-dimethyltryptamine (commonly known as 5-MeO-DMT ). (3) The term State has the meaning given such term in section 901 of title 32, United States Code.